Continuum of type 2 diabetes mellitus and its comorbidity with other somatic diseases

Close metadata

Recommended articles:

Macrovascular and microvascular complications of type 2 diabetes mellitus. Russian Journal of Preventive Medicine. 2024;(8):94-100

Clinical consequences of sarcopenic obesity. Part 1. Non-alcoholic fatty liver disease, type 2 diabetes mellitus, chronic kidney disease. Russian Journal of Preventive Medicine. 2024;(8):114-120

Modulation of oxidative stress as an early symptom of sarcopenia in type 2 diabetes mellitus. Russian Journal of Preventive Medicine. 2024;(10):108-116

Features of comorbidity pathology in young people. Russian Journal of Preventive Medicine. 2024;(11):63-69

Clinical and epidemiological features of atopic type of alopecia areata. Russian Journal of Clinical Dermatology and Venereology. 2024;(2):155-160

Dynamics of outpatient glycemic profile data in patients with type 2 diabetes receiving dietary fiber. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):55-65

Features of cognitive impairment in bipolar affective disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):15-19

Fluvoxamine in the treatment of anxiety-depressive spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):101-109

Anxiety disorders as comorbid conditions in neuropsychiatric diseases in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):56-64

Type 2 diabetes mellitus (DM) develops in several stages over at least 10—15 years. Along with the progression of DM, the synthesis of endogenous insulin is diminished, while excessive glucagon synthesis and peripheral insulin resistance remain. Chronic hyperglycemia and associated multiple pathogenetic factors are responsible for the development of systemic consequences (chronic diabetic complications) and the formation of associations with other somatic diseases. The literature analyzes data on DM comorbidity with hypertension, chronic obstructive pulmonary disease, bronchial asthma, non-alcoholic fatty liver, erectile dysfunction, hypogonadism, and oncological diseases. Comorbid somatic diseases significantly deteriorate patients’ quality and duration of life. Therefore, they shall be considered in the type 2 DM complications-preventing strategy.

Keywords:

type 2 diabetes mellitus

continuum

comorbidity

somatic diseases

Authors:

Mamedov M.N.

National Medical Research Center for Therapy and Preventive Medicine

ORCID: 0000-0001-7131-8049

Druk I.V.

Omsk State Medical University

ORCID: 0000-0001-8317-7765

Arabidze G.G.

Russian Medical Academy of Continuing Professional Education

ORCID: 0000-0003-3370-3506

Akhundova Kh.R.

National Medical Research Center for Therapy and Preventive Medicine;
Russian Medical Academy of Continuing Professional Education

ORCID: 0000-0001-6707-5128

Received:

16.04.2024

Accepted:

23.04.2024

List of references:

International Diabetes Federation. Brussels: International Diabetes Federation; 2021. IDF Diabetes Atlas. Diabetes Around the World in 2021. Accessed June 25, 2024. https://diabetesatlas.org
Khan MAB, Hashim MJ, King JK, et al. Epidemiology of Type 2 Diabetes — Global Burden of Disease and Forecasted Trends. Journal of Epidemiology and Global Health. 2020;10(1):107-111. https://doi.org/10.2991/jegh.k.191028.001
Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice. 2017;128:40-50. https://doi.org/10.1016/j.diabres.2017.03.024
Algoritmy` specializirovannoj medicinskoj pomoshhi bol`ny`m saxarny`m diabetom. Pod red. II Dedova, MV Shestakovoj, AYu Majorova. 11-j vy`pusk (dopolnenny`j). M.; 2023. (In Russ.). https://doi.org/10.14341/DM13042
ESC/EASD 2019 Recommendations on diabetes mellitus, prediabetes and cardiovascular diseases. The Working Group on Diabetes Mellitus, Prediabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC, EOC) and the European Association for the Study of Diabetes Mellitus (EASD, EASDD). Rossijskij kardiologicheskij zhurnal. 2020;25(4):3839. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3839
Jia G, Sowers JR. Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease. Hypertension. 2021;78(5):1197-1205. https://doi.org/10.1161/HYPERTENSIONAHA.121.17981
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm — 2016 Executive summary. Endocrine Practice. 2016;22(1):84-113. https://doi.org/10.4158/EP151126.CS
ElSayed NA, Aleppo G, Aroda VR, et al. American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Care in Diabetes — 2023. Diabetes Care. 2023;46(Suppl. 1):S158-S190. https://doi.org/10.2337/dc23-S010
Kobalava JD, Kolesnik EL, Troitskaya EA. Modern European recommendations on arterial hypertension: updated positions and unresolved issues. Klinicheskaya farmakologiya i terapiya. 2019;28(2):7-18. (In Russ.). https://doi.org/10.32756/0869-5490-2019-2-7-18
Druk IV, Nechaeva GI. Saxarny`j diabet 2-go tipa dlya kardiologov. Pod red. M.N. Mamedova. M.: MIA; 2017. (In Russ.).
Dunlay SM, Givertz MM, Aguilar D, et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Heart Failure Society of America. Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. Journal of Cardiac Failure. 2019;25(8):584-619. https://doi.org/10.1016/j.cardfail.2019.05.007
Zou XZ, Gong ZC, Liu T, et al. Involvement of epithelial-mesenchymal transition afforded by activation of LOX-1/TGF-beta1/KLF6 signaling pathway in diabetic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics. 2017;44:70-77. https://doi.org/10.1016/j.pupt.2017.03.012
Williams JG, Morris AI, Hayter RC, Ogilvie CM. Respiratory responses of diabetics to hypoxia, hypercapnia, and exercise. Thorax. 1984;39(7):529-534. https://doi.org/10.1136/thx.39.7.529
Fontaine-Delaruelle C, Viart-Ferber C, Luyton C, Couraud S. Lung function in patients with diabetes mellitus. Revue de Pneumologie Clinique. 2016; 72(1):10-16. https://doi.org/10.1016/j.pneumo.2015.03.010
Nakajima K, Kubouchi Y, Muneyuki T, et al. Possible association between suspected restrictive pattern as assessed by ordinary pulmonary function test and the metabolic syndrome. Chest. 2008;134(4):712-718. https://doi.org/10.1378/chest.07-3003
Park SS, Perez Perez JL, Perez Gandara B, et al. Mechanisms Linking COPD to Type 1 and 2 Diabetes Mellitus: Is There a Relationship between Diabetes and COPD? Medicina. 2022;58(8):1030. https://doi.org/10.3390/medicina58081030
Khateeb J, Fuchs E, Khamaisi M. Diabetes and Lung Disease: A Neglected Relationship. The Review of Diabetic Studies: RDS. 2019;15:1-15.
Ivashkin VT, Mayevskaya MV, Zharkova MS, et al. Clinical recommendations of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the Russian Association of Endocrinologists, the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology for the diagnosis and treatment of non-alcoholic fatty liver disease. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2022;32(4):104-140. (In Russ.). https://doi.org/10.22416/1382-4376-2022-32-4-104-140
Tanase DM, Gosav EM, Costea CF, et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). Journal of Diabetes Research. 2020; 2020:3920196. https://doi.org/10.1155/2020/3920196
Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes, Obesity and Metabolism. 2021;23(5):1069-1083. https://doi.org/10.1111/dom.14322
Kiseleva EV, Demidova TY. Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the problem of conjugation and phasing of development. Ozhirenie i metabolizm. 2021;18(3):313-319. (In Russ.). https://doi.org/10.14341/omet12758
Dougherty JA, Guirguis E, Thornby KA. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. The Annals of Pharmacotherapy. 2021;55(1):65-79. https://doi.org/10.1177/1060028020935105
Pelusi C. The Effects of the New Therapeutic Treatments for Diabetes Mellitus on the Male Reproductive Axis. Frontiers in Endocrinology. 2022;13: 821113. https://doi.org/10.3389/fendo.2022.821113
Defeudis G, Mazzilli R, Tenuta M, et al. Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. Diabetes/Metabolism Research and Reviews. 2022;38(2):e3494. https://doi.org/10.1002/dmrr.3494
GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736-1788.
Suh S, Kim KW. Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment. Diabetes and Metabolism Journal. 2019;43(6): 733-743. https://doi.org/10.4093/dmj.2019.0177
Shlomai G, Neel B, LeRoith D, Gallagher EJ. Type 2 diabetes mellitus and cancer: the role of pharmacotherapy. Journal of Clinical Oncology. 2016; 34:4261-4269. https://doi.org/10.1200/JCO.2016.67.4044
Wu L, Zhu J, Prokop LJ, Murad MH. Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-analysis of 265 studies. Scientific Reports. 2015;5:10147. https://doi.org/10.1038/srep10147

Close metadata